🇺🇸 FDA

Company profile · Sponsor

Tyra

Tyra Biosciences

TYRA · NYSE pharma CARLSBAD, CA, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Tyra (TYRA) is a pharma company. headquartered in CARLSBAD, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker TYRA
Exchange NYSE
Company type pharma
Headquarters CARLSBAD, CA, USA
SEC CIK 0001863127

Pipeline (9)

Search pipeline →

  1. A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

    Tyra

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

  2. A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

    Tyra

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  3. Dabogratinib (TYRA-300) 60mg

    Tyra

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  4. TYRA-300

    Tyra

    Locally Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. TYRA-300 0.125 mg/kg

    Tyra

    Achondroplasia

    phase 2 small molecule active

    1 trial

  6. TYRA-300 60mg

    Tyra

    Low-grade NMIBC

    phase 2 small molecule active

    1 trial

  7. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  8. TYRA-300-B01

    Tyra

    Healthy

    phase 1 small molecule active

    1 trial

  9. TYRA-430

    Tyra

    Metastatic Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12290069

    Pest control using natural pest control agent blends

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12264149

    Indazole compounds as kinase inhibitors

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12071428

    Indazole compounds as kinase inhibitors

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12035713

    Pest control using natural pest control agent blends

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11896007

    Pest control using natural pest control agent blends

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11116214

    Lice control composition and method

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10881104

    Arthropod control composition, formulation, and method

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10799472

    Antiparasitic compositions and methods

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Tyra?

Tyra (TYRA) is a pharma company. headquartered in CARLSBAD, CA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Tyra sponsor?

We track 9 ClinicalTrials.gov-linked programs for Tyra, including A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301) and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Tyra company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.